On Nov. 1, 2017, FDA announced that it issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these statements.
Here is a selection of articles that we would like to highlight on the site.
Efficient synthesis of complex cannabinoids is possible while avoiding marijuana cultivation.
David Fulper, PhD, director of technology support at Catalent, shares insights on the challenges and opportunities for cannabis-based therapeutics.
On Feb. 7, 2017 GW Pharmaceuticals announced the results from a small Phase II study with tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).
AXIM Biotechnologies, a Netherlands-based biotechnology company, announced that it would be entering clinical trials with its patent-pending cannabigerol (CBG) topical ointment formulation AX-1602, the company said in a May 16, 2016 press
GW Pharmaceuticals, a London-based biopharmaceutical company focused on the development and commercialization of therapeutics derived from its cannabinoid product platform, announced on March 14, 2016 that it had successfully completed a
In an interesting move, FDA sent out eight warning letters on Feb. 4, 2016 to various makers of a dietary supplement called cannabidiol, which is derived from the Cannabis plant.